A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

An Open-Label, Multicenter Study to Evaluate Long-Term Safety and Efficacy of CM512 in Atopic Dermatitis Patients.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07230483

Enrollment

246

Registered

2025-11-17

Start date

2025-12-31

Completion date

2027-12-31

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis (AD)

Brief summary

This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.

Interventions

BIOLOGICALCM512

CM512 subcutaneous injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Have the ability to understand the study and voluntarily sign a written informed consent form (ICF). * Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001.

Exclusion criteria

* Not enough washing-out period for previous therapy. * Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.

Design outcomes

Primary

Measure	Time frame	Description
Adverse events	up to 52 weeks	The incidence of adverse events

Countries

China

Contacts

Primary ContactQian Jia

qianjia@keymedbio.com+86-028-88610620

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026